We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Pfizer Inc. (PFE - Free Report) and its Japanese partner Astellas announced that the FDA has granted priority review to a supplemental new drug application (sNDA) for prostate cancer drug, Xtandi. Pfizer is looking to expand the label of Xtandi to include an early-stage patient population. With the FDA granting priority review, a decision is expected in July.
Pfizer also said that the European Medicines Agency (EMA) has validated a similar label expansion application in Europe.
Shares of Pfizer have returned 1.2% so far this year, almost in line with a 1.3% increase for the industry.
The regulatory applications to add the non-metastatic Castration-Resistant Prostate Cancer (“CRPC”) indication to the drug’s label were based on the results of thePROSPER study on Xtandi.
Detailed data from the phase III PROSPER study on Xtandi showed that treatment with the combination of Xtandi (enzalutamide) and androgen deprivation therapy (“ADT”) reduced the risk of metastases or death by 71% compared with ADT alone in men with non-metastatic CRPC.
In the double-blind study, the median metastasis-free survival (MFS) — the primary endpoint — was 36.6 months with Xtandi plus ADT versus 14.7 months with ADT alone. We remind investors that top-line data from the PROSPER study was presented by Pfizer/Astellas in September 2017.
Many prostate cancer patients with non-metastatic CRPC — an earlier stage of prostate cancer — can experience disease progression despite ADT. However, presently no FDA approved treatment options are available to cater to this until these patients develop metastatic disease i.e. the cancer spreads to other parts of the body.
Xtandi is presently approved for the treatment of metastatic CRPC in patients who have previously received docetaxel. If approved for the non-metastatic patient population, the label of Xtandi can be expanded to cover all patients with CRPC.
Xtandi was added to Pfizer’s portfolio with the acquisition of Medivation in September 2017. While Pfizer sells Xtandi in the United States in partnership with Astellas, the latter owns the marketing right outside the U.S. markets. Pfizer recorded Xtandi alliance revenues of $590 million in 2017.
Some other large-cap pharma stocks worth considering are H. Lundbeck , Glaxo (GSK - Free Report) and Roche (RHHBY - Free Report) , all with the same Zacks Rank as Pfizer.
Shares of H. Lundbeck have returned 12.9% this year so far. Estimates for 2018 have increased 8.5% over the past 60 days.
Glaxo’s shares are up 5.8% this year so far. Over the past 60 days, earnings estimates have risen 5.4% and 3.5%, respectively, for 2018 and 2019.
Over the past 60 days, Roche’s earnings estimates have risen 2.4% and 0.4%, respectively, for 2018 and 2019.
Today's Stocks from Zacks' Hottest Strategies
It's hard to believe, even for us at Zacks. But while the market gained +18.8% from 2016 - Q1 2017, our top stock-picking screens have returned +157.0%, +128.0%, +97.8%, +94.7%, and +90.2% respectively.
And this outperformance has not just been a recent phenomenon. Over the years it has been remarkably consistent. From 2000 - Q1 2017, the composite yearly average gain for these strategies has beaten the market more than 11X over. Maybe even more remarkable is the fact that we're willing to share their latest stocks with you without cost or obligation.
Image: Bigstock
Pfizer's Xtandi Label Expansion Filing Gets Priority Review
Pfizer Inc. (PFE - Free Report) and its Japanese partner Astellas announced that the FDA has granted priority review to a supplemental new drug application (sNDA) for prostate cancer drug, Xtandi. Pfizer is looking to expand the label of Xtandi to include an early-stage patient population. With the FDA granting priority review, a decision is expected in July.
Pfizer also said that the European Medicines Agency (EMA) has validated a similar label expansion application in Europe.
Shares of Pfizer have returned 1.2% so far this year, almost in line with a 1.3% increase for the industry.
The regulatory applications to add the non-metastatic Castration-Resistant Prostate Cancer (“CRPC”) indication to the drug’s label were based on the results of thePROSPER study on Xtandi.
Detailed data from the phase III PROSPER study on Xtandi showed that treatment with the combination of Xtandi (enzalutamide) and androgen deprivation therapy (“ADT”) reduced the risk of metastases or death by 71% compared with ADT alone in men with non-metastatic CRPC.
In the double-blind study, the median metastasis-free survival (MFS) — the primary endpoint — was 36.6 months with Xtandi plus ADT versus 14.7 months with ADT alone. We remind investors that top-line data from the PROSPER study was presented by Pfizer/Astellas in September 2017.
Many prostate cancer patients with non-metastatic CRPC — an earlier stage of prostate cancer — can experience disease progression despite ADT. However, presently no FDA approved treatment options are available to cater to this until these patients develop metastatic disease i.e. the cancer spreads to other parts of the body.
Xtandi is presently approved for the treatment of metastatic CRPC in patients who have previously received docetaxel. If approved for the non-metastatic patient population, the label of Xtandi can be expanded to cover all patients with CRPC.
Xtandi was added to Pfizer’s portfolio with the acquisition of Medivation in September 2017. While Pfizer sells Xtandi in the United States in partnership with Astellas, the latter owns the marketing right outside the U.S. markets. Pfizer recorded Xtandi alliance revenues of $590 million in 2017.
Zacks Rank & Other Stocks to Consider
Pfizer carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Some other large-cap pharma stocks worth considering are H. Lundbeck , Glaxo (GSK - Free Report) and Roche (RHHBY - Free Report) , all with the same Zacks Rank as Pfizer.
Shares of H. Lundbeck have returned 12.9% this year so far. Estimates for 2018 have increased 8.5% over the past 60 days.
Glaxo’s shares are up 5.8% this year so far. Over the past 60 days, earnings estimates have risen 5.4% and 3.5%, respectively, for 2018 and 2019.
Over the past 60 days, Roche’s earnings estimates have risen 2.4% and 0.4%, respectively, for 2018 and 2019.
Today's Stocks from Zacks' Hottest Strategies
It's hard to believe, even for us at Zacks. But while the market gained +18.8% from 2016 - Q1 2017, our top stock-picking screens have returned +157.0%, +128.0%, +97.8%, +94.7%, and +90.2% respectively.
And this outperformance has not just been a recent phenomenon. Over the years it has been remarkably consistent. From 2000 - Q1 2017, the composite yearly average gain for these strategies has beaten the market more than 11X over. Maybe even more remarkable is the fact that we're willing to share their latest stocks with you without cost or obligation.
See Them Free>>